Female reproductive system neoplasm
Therapeutic area
Reproductive Health
Rare disease
No
- Definition
- A benign, precancerous, or malignant neoplasm that affects the female reproductive system. Representative examples include uterine corpus leiomyoma, endocervical polyp, ovarian carcinoma, cervical carcinoma, and endometrial carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Female reproductive system neoplasm
- Therapeutic area
- Reproductive Health
- female reproductive system neoplasm
- Advanced Gynecologic Tumors
- female reproductive organ neoplasm (disease)
- female reproductive organ tumor
- female reproductive organ tumour
- female reproductive system neoplasm (disease)
- female reproductive system tumor
- female reproductive system tumour
- gynecologic neoplasm
- gynecologic tumor
- Gynecologic Tumors
- gynecologic tumour
- neoplasm of female reproductive organ
- neoplasm of female reproductive system
- neoplasm of the female reproductive system
- Neoplasm, Gynecologic
- tumor of female reproductive system
- tumor of the female reproductive system
- tumour of female reproductive system
- tumour of the female reproductive system
- Severity
- Severe
- Oncology
- Reproductive Health
Sources for recorded values
- MONDO ID
- MONDO:0021148
- Parent condition
- MONDO:0002263
Related records
Broader conditions (10)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Female reproductive system disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (455)
- Adenocarcinofibroma
- Adenocarcinoma of skene gland origin
- Adenofibroma
- Adenoid cystic carcinoma of the corpus uteri
- Adenomyoma
- Adenomyoma of uterine corpus
- Adenosarcoma
- Adult vagina botryoid embryonal rhabdomyosarcoma
- Atypical Meigs syndrome
- Atypical polypoid adenomyoma
- Bartholin gland adenocarcinoma
- Bartholin gland adenoid cystic carcinoma
- Bartholin gland adenoma
- Bartholin gland adenomyoma
- Bartholin gland adenosquamous carcinoma
- Bartholin gland benign neoplasm
- Bartholin gland carcinoma
- Bartholin gland neoplasm
- Bartholin gland small cell carcinoma
- Bartholin gland squamous cell carcinoma
Trials (81)
- A Cohort Establishment Study of Total Management of Ovarian Cancer
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
- A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
- A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
- A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
- A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
- A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
- A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
- A Trial for Patients With Advanced/Recurrent Cervical Cancer
- A Trial for Patients With Advanced/Recurrent Endometrial Cancer
- AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
- Adherence and Compliance to ERAS in Gynecological Surgery
- An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
- Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Drugs in development (21)
- Abemaciclib Phase 1
- Avutometinib Phase 2
- Bulumtatug fuvedotin Phase 1
- Carboplatin Phase 2
- Cisplatin Phase 1
- Defactinib Phase 2
- Doxorubicin Phase 2
- Endoxifen Phase 1
- Ferric carboxymaltose Phase 3
- Gadobutrol Phase 1
- Heparin Phase 3
- Lucitanib Phase 1
- Monalizumab Phase 1
- Nivolumab Phase 1
- Paclitaxel Phase 3
- Pembrolizumab Phase 2
- Piflufolastat F18 Phase 2
- Prasterone Phase 3
- Satraplatin Phase 1
- Tranexamic acid Phase 3
Other linked drugs (1)
- Dimenhydrinate